These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 11089235)

  • 41. Apoptosis induced by the homocamptothecin anticancer drug BN80915 in HL-60 cells.
    Lansiaux A; Facompré M; Wattez N; Hildebrand MP; Bal C; Demarquay D; Lavergne O; Bigg DC; Bailly C
    Mol Pharmacol; 2001 Sep; 60(3):450-61. PubMed ID: 11502875
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cytotoxic action and cell cycle effects of ALGA, a peptidic derivative of the antileukemic drug amsacrine.
    Collyn-d'Hooghe M; Bernier JL; Henichart JP
    Cancer Biochem Biophys; 1987 Sep; 9(3):257-64. PubMed ID: 3435897
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Enhanced sensitivity to topoisomerase inhibitors in synchronous CHO cells pre-treated with 5-azacytidine.
    López-Baena M; Mateos S; Piñero J; Trinidad Ortiz ; Cortés F
    Mutat Res; 1998 Oct; 421(1):109-16. PubMed ID: 9748527
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Miniaturizing bromodeoxyuridine incorporation enables the usage of flow cytometry for cell cycle analysis of adherent tissue culture cells for high throughput screening.
    Cappella P; Giorgini ML; Ernestina Re C; Ubezio P; Ciomei M; Moll J
    Cytometry A; 2010 Oct; 77(10):953-61. PubMed ID: 21290469
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Topoisomerase I inhibitors. An overview of the camptothecin analogs.
    Burris HA; Fields SM
    Hematol Oncol Clin North Am; 1994 Apr; 8(2):333-55. PubMed ID: 8040144
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cell cycle kinetics estimated by analysis of bromodeoxyuridine incorporation.
    Terry NH; White RA
    Methods Cell Biol; 2001; 63():355-74. PubMed ID: 11060849
    [No Abstract]   [Full Text] [Related]  

  • 47. Differences in induction of p53, p21WAF1 and apoptosis in relation to cell cycle phase of MCF-7 cells treated with camptothecin.
    Deptala A; Li X; Bedner E; Cheng W; Traganos F; Darzynkiewicz Z
    Int J Oncol; 1999 Nov; 15(5):861-71. PubMed ID: 10536167
    [TBL] [Abstract][Full Text] [Related]  

  • 48. DNA synthesis inhibition as an indirect mechanism of chromosome aberrations: comparison of DNA-reactive and non-DNA-reactive clastogens.
    Galloway SM; Miller JE; Armstrong MJ; Bean CL; Skopek TR; Nichols WW
    Mutat Res; 1998 May; 400(1-2):169-86. PubMed ID: 9685628
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Discrimination of G2 and mitotic cells by flow cytometry based on different expression of cyclins A and B1.
    Gong J; Traganos F; Darzynkiewicz Z
    Exp Cell Res; 1995 Sep; 220(1):226-31. PubMed ID: 7664839
    [TBL] [Abstract][Full Text] [Related]  

  • 50. BN 80927: a novel homocamptothecin with inhibitory activities on both topoisomerase I and topoisomerase II.
    Lavergne O; Harnett J; Rolland A; Lanco C; Lesueur-Ginot L; Demarquay D; Huchet M; Coulomb H; Bigg DC
    Bioorg Med Chem Lett; 1999 Sep; 9(17):2599-602. PubMed ID: 10498216
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New cell cycle compartments identified by multiparameter flow cytometry.
    Darzynkiewicz Z; Traganos F; Melamed MR
    Cytometry; 1980 Sep; 1(2):98-108. PubMed ID: 6170495
    [No Abstract]   [Full Text] [Related]  

  • 52. Assessment of histone H2AX phosphorylation induced by DNA topoisomerase I and II inhibitors topotecan and mitoxantrone and by the DNA cross-linking agent cisplatin.
    Huang X; Okafuji M; Traganos F; Luther E; Holden E; Darzynkiewicz Z
    Cytometry A; 2004 Apr; 58(2):99-110. PubMed ID: 15057963
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cross-resistance of an amsacrine-resistant human leukemia line to topoisomerase II reactive DNA intercalating agents. Evidence for two topoisomerase II directed drug actions.
    Zwelling LA; Mayes J; Hinds M; Chan D; Altschuler E; Carroll B; Parker E; Deisseroth K; Radcliffe A; Seligman M
    Biochemistry; 1991 Apr; 30(16):4048-55. PubMed ID: 1850298
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The cell cycle effects of camptothecin.
    Darzynkiewicz Z; Bruno S; Del Bino G; Traganos F
    Ann N Y Acad Sci; 1996 Dec; 803():93-100. PubMed ID: 8993503
    [No Abstract]   [Full Text] [Related]  

  • 55. DNA topoisomerase I and II in cancer chemotherapy: update and perspectives.
    Pommier Y
    Cancer Chemother Pharmacol; 1993; 32(2):103-8. PubMed ID: 8387398
    [No Abstract]   [Full Text] [Related]  

  • 56. DNA topoisomerase I poisons.
    Takimoto CH; Kieffer LV; Kieffer ME; Arbuck SG; Wright J
    Cancer Chemother Biol Response Modif; 1999; 18():81-124. PubMed ID: 10800479
    [No Abstract]   [Full Text] [Related]  

  • 57. Induction of apoptosis by camptothecin and topotecan.
    Traganos F; Seiter K; Feldman E; Halicka HD; Darzynkiewicz Z
    Ann N Y Acad Sci; 1996 Dec; 803():101-10. PubMed ID: 8993504
    [No Abstract]   [Full Text] [Related]  

  • 58. Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase-I: evidence for cell cycle-independent toxicity.
    Morris EJ; Geller HM
    J Cell Biol; 1996 Aug; 134(3):757-70. PubMed ID: 8707853
    [TBL] [Abstract][Full Text] [Related]  

  • 59. DNA measurement and cell cycle analysis by flow cytometry.
    Nunez R
    Curr Issues Mol Biol; 2001 Jul; 3(3):67-70. PubMed ID: 11488413
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cell cycle dependence of sister chromatid exchange induction by DNA topoisomerase II inhibitors in Chinese hamster V79 cells.
    Dillehay LE; Denstman SC; Williams JR
    Cancer Res; 1987 Jan; 47(1):206-9. PubMed ID: 3024815
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.